Immediately after the announcement, politicians began falling over themselves to hand fat checks over to the Big Pharma giants, hoping that the news would inspire hope in their public. Many parts of the media treated it likewise as a crushing blow to the coronavirus; the Economist called it “the beginning of the end.” But not everyone shares their optimism. Concerns are emerging about how practical the Pfizer vaccine could be, requiring as it does hugely expensive supporting equipment.
Straight from the fridge
The Pfizer vaccine uses messenger RNA (mRNA) to combat the virus, an advanced genetic therapy that uses the virus’ own genetic material against it. Because mRNA is in a sense a living molecule, the vaccines have to be constantly kept at extremely low temperatures: -70 degrees Celsius or -94 Fahrenheit to be exact. And that is the maximum: ideally they would be even cooler.
This takes freezers. Big, expensive ones, and lots of them at that. The vaccine can only be stored in a normal refrigerator, like one you would have in your kitchen, for five days prior to use. After that they spoil, but the boffins are currently working to extend that period to two weeks. Opening the freezer as little as possible also helps.
ALSO ON RT.COMFlu away: Scientists baffled at disappearance of influenza… but is it really gone, or just masked by Covid-19?While initial reactions were white hot, many health policy makers seem to be going cold on the idea of Pfizer’s vaccine. This report outlines how the East Asian nations, especially the poorer ones like Vietnam, Indonesia, and the Philippines, are not keen on the idea of splashing out for God knows how many giant freezers which would have to survive journeys to remote communities in difficult terrain or on distant islands. Not to mention the weather, which in warmer climes will make the energy demands even greater.
But it is not just the poor countries that are worried. South Korea and Japan claim to not currently have the cold storage space for a Pfizer-type vaccine. If this is how Asian countries are reacting – countries that were widely praised for their technological approach to handling the outbreak – how could this work in Latin America and Africa?
In fact, even the most sophisticated American hospitals in big cities have nothing like the capacity to store Pfizer vaccines. And according to one publication, nothing less than “a gigantic new network of freezers” will do.
Pfizer themselves claim to have “developed packaging and storage innovations to be fit for purpose for the range of locations where we believe vaccinations will take place.” Apparently it involves using dry ice to transport the vaccine by land and air. That is all very well in theory, but again, it is difficult to look past the scale of military-style operation this sort of thing would entail.
But with problems this complicated, the true scale of the challenge will not become apparent until it has begun. Governments, at least in Western Europe, have a tendency to spend money first and ask questions later when it comes to fancy equipment. The Irish government, for example, last year spent over €2 million on a single printer for their parliamentary buildings. If that is anything to go by, perhaps they will splurge on the freezers.
Politicians are absolutely right to be expressing these concerns about the logistical nightmare the Pfizer vaccine appears to present. Any vaccination programme is a massive undertaking, but Covid vaccines in particular have a host of additional challenges baked in. The accelerated timeline they are being developed at, the confusion over who is to be served first and the apparent lack of enthusiasm from the public for even getting them at all.Big Pharma wars
One former Big Pharma honcho was particularly scathing about the way in which Pfizer announced their early results. He called it “a cynical and egregious marketing ploy by Pfizer to get early orders’’ and said that Pfizer “know that mass vaccination with a vaccine that needs storage at -80 degrees is completely unworkable.” It should be noted that this is a former director of rival firm GSK, and so there may be some company pride at stake. But he is certainly not alone, as many experts are doubtful that a large roll out of this vaccine is at all feasible.
All of this said, it looks like Pfizer’s boss has done just fine from the announcement.
Think your friends would be interested? Share this story!